Pfizer profit surges, reaffirms sales forecast for COVID-19 products
2022.07.28 15:09
2/2
FILE PHOTO: Vials of the Pfizer-BioNTech Comirnaty coronavirus disease (COVID-19) vaccine are pictured in a General practitioners practice in Berlin, Germany, April 10, 2021. REUTERS/Fabrizio Bensch/File Photo
2/2
(Reuters) -Pfizer Inc on Thursday reported a 78% jump in profit and reaffirmed the combined 2022 sales forecast of $54 billion for its COVID-19 vaccine and pill, as countries rushed to sign contracts to prepare for a surge of cases in the fall season.
Shares rose 1.8% in premarket trading as overall net income rose to $9.91 billion despite a stronger dollar, thanks to strong demand for the vaccine as well as its antiviral treatment Paxlovid.
Demand for the pill, which was used by President Joe Biden during his bout of COVID-19 infection, has picked up recently in the United States and other countries due to fresh outbreaks.
Pfizer (NYSE:PFE) has been banking on demand for vaccine boosters to drive up sales for the next few years.
The company and its partner BioNTech last month signed a $3.2 billion deal with the U.S. government for 105 million doses of their vaccine, which includes supply of retooled Omicron-adapted booster, pending regulatory clearance.
